TaiGen Biotechnology Company, Limited announces that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study.
TaiGen Biotechnology Company, Limited announces that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study.